Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)

NCT05551598 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Neuromyelitis Optica Spectrum Disorder

Interventions

DRUG: Mitoxantrone Hydrochloride Liposome Injection

Sponsor

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.